Identification of a Gene Signature That Predicts Dependence upon YAP/TAZ-TEAD
Ryan Kanai1, Emily Norton1, Patrick Stern2
1Department of Molecular and Cellular Physiology, Albany Medical College, Albany, NY 12208, USA.
Cancers
|March 13, 2024
Summary
Researchers developed a YAP/TAZ gene signature to identify cancers dependent on the YAP/TAZ-TEAD pathway. This signature predicts patient response to TEAD inhibitors, aiding targeted cancer therapy selection.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- Targeted cancer therapies require accurate diagnostics to identify responsive patients.
- The YAP/TAZ-TEAD signaling pathway is implicated in various cancers.
- Current limitations exist in identifying tumors with YAP/TAZ-TEAD activation for effective TEAD inhibitor treatment.
Purpose of the Study:
- To develop a reliable YAP/TAZ gene signature for identifying tumors susceptible to TEAD inhibitors.
- To assess the predictive capability of the YAP/TAZ signature across diverse cancer types.
Main Methods:
- RNA sequencing and bioinformatic analysis of metastatic melanoma cells.
- Development and validation of a YAP/TAZ gene expression signature.
- Utilizing DepMap dependency data to evaluate signature's predictive power.
Main Results:
- A YAP/TAZ gene signature was successfully developed and validated in melanoma.
- The signature's gene expression correlates with YAP/TAZ activation in human melanomas.
- The signature accurately predicted YAP/TAZ or TEAD dependency in over 1000 cancer cell lines, extending beyond melanoma.
Conclusions:
- YAP/TAZ gene signatures can effectively predict tumor cell dependence on the YAP/TAZ-TEAD pathway.
- This approach offers a potential method for identifying patients who may benefit from TEAD inhibitor therapies.
- The developed signature holds promise for guiding personalized cancer treatment strategies.
